{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T10:52:11Z","timestamp":1785149531108,"version":"3.55.0"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,12,19]],"date-time":"2022-12-19T00:00:00Z","timestamp":1671408000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,12,19]],"date-time":"2022-12-19T00:00:00Z","timestamp":1671408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1038\/s41401-022-01030-1","type":"journal-article","created":{"date-parts":[[2022,12,19]],"date-time":"2022-12-19T08:03:14Z","timestamp":1671436994000},"page":"1135-1148","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Pazopanib alleviates neuroinflammation and protects dopaminergic neurons in LPS-stimulated mouse model by inhibiting MEK4-JNK-AP-1 pathway"],"prefix":"10.1038","volume":"44","author":[{"given":"Hong-yang","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0415lena","family":"Kaznacheyeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-jun","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-gang","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang-hui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,19]]},"reference":[{"key":"1030_CR1","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41572-021-00280-3","volume":"7","author":"D Aarsland","year":"2021","unstructured":"Aarsland D, Batzu L, Halliday GM, Geurtsen GJ, Ballard C, Ray Chaudhuri K, et al. Parkinson disease-associated cognitive impairment. Nat Rev Dis Prim. 2021;7:47.","journal-title":"Nat Rev Dis Prim"},{"key":"1030_CR2","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S1474-4422(18)30295-3","volume":"17","author":"Collaborators GBDPsD.","year":"2018","unstructured":"Collaborators GBDPsD. Global, regional, and national burden of Parkinson\u2019s disease, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018;17:939\u201353.","journal-title":"Lancet Neurol"},{"key":"1030_CR3","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.bbi.2013.07.007","volume":"33","author":"D Lindqvist","year":"2013","unstructured":"Lindqvist D, Hall S, Surova Y, Nielsen HM, Janelidze S, Brundin L, et al. Cerebrospinal fluid inflammatory markers in Parkinson\u2019s disease-associations with depression, fatigue, and cognitive impairment. Brain Behav Immun. 2013;33:183\u20139.","journal-title":"Brain Behav Immun"},{"key":"1030_CR4","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1080\/15548627.2020.1719723","volume":"16","author":"J Cheng","year":"2020","unstructured":"Cheng J, Liao Y, Dong Y, Hu H, Yang N, Kong X, et al. Microglial autophagy defect causes parkinson disease-like symptoms by accelerating inflammasome activation in mice. Autophagy. 2020;16:2193\u2013205.","journal-title":"Autophagy"},{"key":"1030_CR5","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1126\/science.aaf3934","volume":"357","author":"S Mittal","year":"2017","unstructured":"Mittal S, Bjornevik K, Im DS, Flierl A, Dong X, Locascio JJ, et al. beta2-Adrenoreceptor is a regulator of the alpha-synuclein gene driving risk of Parkinson\u2019s disease. Science. 2017;357:891\u20138.","journal-title":"Science"},{"key":"1030_CR6","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s40035-020-00217-y","volume":"9","author":"M Lemos","year":"2020","unstructured":"Lemos M, Venezia S, Refolo V, Heras-Garvin A, Schmidhuber S, Giese A, et al. Targeting alpha-synuclein by PD03 AFFITOPE(R) and Anle138b rescues neurodegenerative pathology in a model of multiple system atrophy: clinical relevance. Transl Neurodegener. 2020;9:38.","journal-title":"Transl Neurodegener"},{"key":"1030_CR7","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1080\/15548627.2017.1302045","volume":"13","author":"SN Suresh","year":"2017","unstructured":"Suresh SN, Chavalmane AK, Dj V, Yarreiphang H, Rai S, Paul A, et al. A novel autophagy modulator 6-Bio ameliorates SNCA\/alpha-synuclein toxicity. Autophagy. 2017;13:1221\u201334.","journal-title":"Autophagy"},{"key":"1030_CR8","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1080\/15548627.2018.1491489","volume":"14","author":"AR Issa","year":"2018","unstructured":"Issa AR, Sun J, Petitgas C, Mesquita A, Dulac A, Robin M, et al. The lysosomal membrane protein LAMP2A promotes autophagic flux and prevents SNCA-induced Parkinson disease-like symptoms in the Drosophila brain. Autophagy. 2018;14:1898\u2013910.","journal-title":"Autophagy"},{"key":"1030_CR9","doi-asserted-by":"publisher","first-page":"26438","DOI":"10.1073\/pnas.2009838117","volume":"117","author":"DE Mor","year":"2020","unstructured":"Mor DE, Sohrabi S, Kaletsky R, Keyes W, Tartici A, Kalia V, et al. Metformin rescues Parkinson\u2019s disease phenotypes caused by hyperactive mitochondria. Proc Natl Acad Sci USA. 2020;117:26438\u201347.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1030_CR10","doi-asserted-by":"publisher","first-page":"259","DOI":"10.4172\/2155-9899.1000259","volume":"5","author":"ML Hebron","year":"2014","unstructured":"Hebron ML, Lonskaya I, Olopade P, Selby ST, Pagan F, Moussa CE. Tyrosine kinase inhibition regulates early systemic immune changes and modulates the neuroimmune response in alpha-synucleinopathy. J Clin Cell Immunol. 2014;5:259.","journal-title":"J Clin Cell Immunol"},{"key":"1030_CR11","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1093\/brain\/awz104","volume":"142","author":"CW Olanow","year":"2019","unstructured":"Olanow CW, Savolainen M, Chu Y, Halliday GM, Kordower JH. Temporal evolution of microglia and alpha-synuclein accumulation following foetal grafting in Parkinson\u2019s disease. Brain. 2019;142:1690\u2013700.","journal-title":"Brain"},{"key":"1030_CR12","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1002\/glia.24149","volume":"70","author":"P Garcia","year":"2022","unstructured":"Garcia P, Jurgens-Wemheuer W, Uriarte Huarte O, Michelucci A, Masuch A, Brioschi S, et al. Neurodegeneration and neuroinflammation are linked, but independent of alpha-synuclein inclusions, in a seeding\/spreading mouse model of Parkinson\u2019s disease. Glia. 2022;70:935\u201360.","journal-title":"Glia"},{"key":"1030_CR13","doi-asserted-by":"publisher","first-page":"891","DOI":"10.3233\/JPD-219006","volume":"11","author":"K McFarthing","year":"2021","unstructured":"McFarthing K, Rafaloff G, Baptista MAS, Wyse RK, Stott SRW. Parkinson\u2019s disease drug therapies in the clinical trial pipeline: 2021 update. J Parkinsons Dis. 2021;11:891\u2013903.","journal-title":"J Parkinsons Dis"},{"key":"1030_CR14","doi-asserted-by":"publisher","first-page":"4647","DOI":"10.3390\/ijms22094676","volume":"22","author":"K Badanjak","year":"2021","unstructured":"Badanjak K, Fixemer S, Smajic S, Skupin A, Grunewald A. The contribution of microglia to neuroinflammation in Parkinson\u2019s disease. Int J Mol Sci. 2021;22:4647.","journal-title":"Int J Mol Sci"},{"key":"1030_CR15","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/s41582-019-0204-2","volume":"15","author":"S Lempriere","year":"2019","unstructured":"Lempriere S. Age-related microglial activation accelerated in AD. Nat Rev Neurol. 2019;15:369.","journal-title":"Nat Rev Neurol"},{"key":"1030_CR16","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.neuropharm.2015.04.037","volume":"97","author":"BW Kim","year":"2015","unstructured":"Kim BW, Koppula S, Kumar H, Park JY, Kim IW, More SV, et al. alpha-Asarone attenuates microglia-mediated neuroinflammation by inhibiting NF kappa B activation and mitigates MPTP-induced behavioral deficits in a mouse model of Parkinson\u2019s disease. Neuropharmacology. 2015;97:46\u201357.","journal-title":"Neuropharmacology"},{"key":"1030_CR17","doi-asserted-by":"publisher","first-page":"451","DOI":"10.3390\/nu9050451","volume":"9","author":"S More","year":"2017","unstructured":"More S, Choi DK. Neuroprotective role of Atractylenolide-I in an in vitro and in vivo model of Parkinson\u2019s disease. Nutrients. 2017;9:451.","journal-title":"Nutrients"},{"key":"1030_CR18","doi-asserted-by":"publisher","first-page":"441","DOI":"10.3389\/fnmol.2017.00441","volume":"10","author":"GQ Wang","year":"2017","unstructured":"Wang GQ, Li DD, Huang C, Lu DS, Zhang C, Zhou SY, et al. Icariin reduces dopaminergic neuronal loss and microglia-mediated inflammation in vivo and in vitro. Front Mol Neurosci. 2017;10:441.","journal-title":"Front Mol Neurosci"},{"key":"1030_CR19","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1001\/archneur.60.8.1059","volume":"60","author":"H Chen","year":"2003","unstructured":"Chen H, Zhang SM, Hernan MA, Schwarzschild MA, Willett WC, Colditz GA, et al. Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch Neurol. 2003;60:1059\u201364.","journal-title":"Arch Neurol"},{"key":"1030_CR20","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1212\/WNL.0b013e3181d5a4a3","volume":"74","author":"JJ Gagne","year":"2010","unstructured":"Gagne JJ, Power MC. Anti-inflammatory drugs and risk of Parkinson disease: a meta-analysis. Neurology. 2010;74:995\u20131002.","journal-title":"Neurology"},{"key":"1030_CR21","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/s41401-020-0379-5","volume":"41","author":"CH Guo","year":"2020","unstructured":"Guo CH, Cao T, Zheng LT, Waddington JL, Zhen XC. Development and characterization of an inducible Dicer conditional knockout mouse model of Parkinson\u2019s disease: validation of the antiparkinsonian effects of a sigma-1 receptor agonist and dihydromyricetin. Acta Pharmacol Sin. 2020;41:499\u2013507.","journal-title":"Acta Pharmacol Sin"},{"key":"1030_CR22","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1038\/aps.2016.42","volume":"37","author":"ZX Ren","year":"2016","unstructured":"Ren ZX, Zhao YF, Cao T, Zhen XC. Dihydromyricetin protects neurons in an MPTP-induced model of Parkinson\u2019s disease by suppressing glycogen synthase kinase-3 beta activity. Acta Pharmacol Sin. 2016;37:1315\u201324.","journal-title":"Acta Pharmacol Sin"},{"key":"1030_CR23","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.bbi.2020.10.014","volume":"91","author":"J Sun","year":"2021","unstructured":"Sun J, Li H, Jin Y, Yu J, Mao S, Su KP, et al. Probiotic Clostridium butyricum ameliorated motor deficits in a mouse model of Parkinson\u2019s disease via gut microbiota-GLP-1 pathway. Brain Behav Immun. 2021;91:703\u201315.","journal-title":"Brain Behav Immun"},{"key":"1030_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10956-w","volume":"10","author":"Z Hao","year":"2019","unstructured":"Hao Z, Liu L, Tao Z, Wang R, Ren H, Sun H, et al. Motor dysfunction and neurodegeneration in a C9orf72 mouse line expressing poly-PR. Nat Commun. 2019;10:2906.","journal-title":"Nat Commun"},{"key":"1030_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-018-1189-2","volume":"9","author":"M Cao","year":"2018","unstructured":"Cao M, Chen F, Xie N, Cao MY, Chen P, Lou Q, et al. c-Jun N-terminal kinases differentially regulate TNF- and TLRs-mediated necroptosis through their kinase-dependent and -independent activities. Cell Death Dis. 2018;9:1140.","journal-title":"Cell Death Dis"},{"key":"1030_CR26","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1038\/aps.2016.68","volume":"37","author":"YX Yu","year":"2016","unstructured":"Yu YX, Li YP, Gao F, Hu QS, Zhang Y, Chen D, et al. Vitamin K2 suppresses rotenone-induced microglial activation in vitro. Acta Pharmacol Sin. 2016;37:1178\u201389.","journal-title":"Acta Pharmacol Sin"},{"key":"1030_CR27","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41401-018-0064-0","volume":"40","author":"DK Guo","year":"2019","unstructured":"Guo DK, Zhu Y, Sun HY, Xu XY, Zhang S, Hao ZB, et al. Pharmacological activation of REV-ERBalpha represses LPS-induced microglial activation through the NF-kappaB pathway. Acta Pharmacol Sin. 2019;40:26\u201334.","journal-title":"Acta Pharmacol Sin"},{"key":"1030_CR28","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1038\/s41401-019-0225-9","volume":"40","author":"CJ Han","year":"2019","unstructured":"Han CJ, Zheng JY, Sun L, Yang HC, Cao ZQ, Zhang XH, et al. The oncometabolite 2-hydroxyglutarate inhibits microglial activation via the AMPK\/mTOR\/NF-kappaB pathway. Acta Pharmacol Sin. 2019;40:1292\u2013302.","journal-title":"Acta Pharmacol Sin"},{"key":"1030_CR29","doi-asserted-by":"publisher","first-page":"400","DOI":"10.3389\/fncel.2018.00400","volume":"12","author":"C Gu","year":"2018","unstructured":"Gu C, Hu Q, Wu J, Mu C, Ren H, Liu CF, et al. P7C3 inhibits LPS-induced microglial activation to protect dopaminergic neurons against inflammatory factor-induced cell death in vitro and in vivo. Front Cell Neurosci. 2018;12:400.","journal-title":"Front Cell Neurosci"},{"key":"1030_CR30","doi-asserted-by":"publisher","first-page":"889383","DOI":"10.3389\/fphar.2022.889383","volume":"13","author":"J Fang","year":"2022","unstructured":"Fang J, She J, Lin F, Wu JC, Han R, Sheng R, et al. RRx-001 exerts neuroprotection against LPS-induced microglia activation and neuroinflammation through disturbing the TLR4 pathway. Front Pharmacol. 2022;13:889383.","journal-title":"Front Pharmacol"},{"key":"1030_CR31","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1038\/s41401-021-00698-1","volume":"43","author":"XL Yan","year":"2022","unstructured":"Yan XL, Xu FY, Ji JJ, Song P, Pei YQ, He MJ, et al. Activation of UCP2 by anethole trithione suppresses neuroinflammation after intracerebral hemorrhage. Acta Pharmacol Sin. 2022;43:811\u201328.","journal-title":"Acta Pharmacol Sin"},{"key":"1030_CR32","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1038\/s41573-022-00390-x","volume":"21","author":"HG Lee","year":"2022","unstructured":"Lee HG, Wheeler MA, Quintana FJ. Function and therapeutic value of astrocytes in neurological diseases. Nat Rev Drug Discov. 2022;21:339\u201358.","journal-title":"Nat Rev Drug Discov"},{"key":"1030_CR33","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/nature21029","volume":"541","author":"SA Liddelow","year":"2017","unstructured":"Liddelow SA, Guttenplan KA, Clarke LE, Bennett FC, Bohlen CJ, Schirmer L, et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature. 2017;541:481\u20137.","journal-title":"Nature"},{"key":"1030_CR34","doi-asserted-by":"publisher","first-page":"3091","DOI":"10.1517\/14656560903436493","volume":"10","author":"S Limvorasak","year":"2009","unstructured":"Limvorasak S, Posadas EM. Pazopanib: therapeutic developments. Expert Opin Pharmacother. 2009;10:3091\u2013102.","journal-title":"Expert Opin Pharmacother"},{"key":"1030_CR35","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/nrc780","volume":"2","author":"M Karin","year":"2002","unstructured":"Karin M, Cao Y, Greten FR, Li ZW. NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer. 2002;2:301\u201310.","journal-title":"Nat Rev Cancer"},{"key":"1030_CR36","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.tim.2010.08.003","volume":"18","author":"S Backert","year":"2010","unstructured":"Backert S, Naumann M. What a disorder: proinflammatory signaling pathways induced by Helicobacter pylori. Trends Microbiol. 2010;18:479\u201386.","journal-title":"Trends Microbiol"},{"key":"1030_CR37","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1038\/nrc2734","volume":"9","author":"H Yu","year":"2009","unstructured":"Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer. 2009;9:798\u2013809.","journal-title":"Nat Rev Cancer"},{"key":"1030_CR38","doi-asserted-by":"publisher","first-page":"9641","DOI":"10.1523\/JNEUROSCI.0828-10.2010","volume":"30","author":"K Nagamoto-Combs","year":"2010","unstructured":"Nagamoto-Combs K, Combs CK. Microglial phenotype is regulated by activity of the transcription factor, NFAT (nuclear factor of activated T cells). J Neurosci. 2010;30:9641\u20136.","journal-title":"J Neurosci"},{"key":"1030_CR39","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nri3446","volume":"13","author":"LA O\u2019Neill","year":"2013","unstructured":"O\u2019Neill LA, Golenbock D, Bowie AG. The history of Toll-like receptors\u2014redefining innate immunity. Nat Rev Immunol. 2013;13:453\u201360.","journal-title":"Nat Rev Immunol"},{"key":"1030_CR40","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.3389\/fimmu.2019.01107","volume":"10","author":"T Dainichi","year":"2019","unstructured":"Dainichi T, Matsumoto R, Mostafa A, Kabashima K. Immune control by TRAF6-Mediated pathways of epithelial cells in the EIME (Epithelial Immune Microenvironment). Front Immunol. 2019;10:1107.","journal-title":"Front Immunol"},{"key":"1030_CR41","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/s41577-019-0262-0","volume":"20","author":"M Colonna","year":"2020","unstructured":"Colonna M, Brioschi S. Neuroinflammation and neurodegeneration in human brain at single-cell resolution. Nat Rev Immunol. 2020;20:81\u20132.","journal-title":"Nat Rev Immunol"},{"key":"1030_CR42","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/S1474-4422(18)30394-6","volume":"18","author":"DR Beers","year":"2019","unstructured":"Beers DR, Appel SH. Immune dysregulation in amyotrophic lateral sclerosis: mechanisms and emerging therapies. Lancet Neurol. 2019;18:211\u201320.","journal-title":"Lancet Neurol"},{"key":"1030_CR43","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.nbd.2005.08.002","volume":"21","author":"A Gerhard","year":"2006","unstructured":"Gerhard A, Pavese N, Hotton G, Turkheimer F, Es M, Hammers A, et al. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson\u2019s disease. Neurobiol Dis. 2006;21:404\u201312.","journal-title":"Neurobiol Dis"},{"key":"1030_CR44","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/s41401-020-0369-7","volume":"41","author":"XC Zhen","year":"2020","unstructured":"Zhen XC, Chu HY. Emerging novel approaches to drug research and diagnosis of Parkinson\u2019s disease. Acta Pharmacol Sin. 2020;41:439\u201341.","journal-title":"Acta Pharmacol Sin"},{"key":"1030_CR45","doi-asserted-by":"publisher","first-page":"e00841","DOI":"10.1002\/prp2.841","volume":"9","author":"EJR Fletcher","year":"2021","unstructured":"Fletcher EJR, Kaminski T, Williams G, Duty S. Drug repurposing strategies of relevance for Parkinson\u2019s disease. Pharm Res Perspect. 2021;9:e00841.","journal-title":"Pharm Res Perspect"},{"key":"1030_CR46","doi-asserted-by":"publisher","first-page":"174800","DOI":"10.1016\/j.ejphar.2022.174800","volume":"919","author":"BD Arbo","year":"2022","unstructured":"Arbo BD, Schimith LE, Goulart Dos Santos M, Hort MA. Repositioning and development of new treatments for neurodegenerative diseases: Focus on neuroinflammation. Eur J Pharmacol. 2022;919:174800.","journal-title":"Eur J Pharmacol"},{"key":"1030_CR47","doi-asserted-by":"publisher","first-page":"879690","DOI":"10.3389\/fphar.2022.879690","volume":"13","author":"G Zhang","year":"2022","unstructured":"Zhang G, Chen S, Jia J, Liu C, Wang W, Zhang H, et al. Development and evaluation of novel metformin derivative metformin threonate for brain Ischemia treatment. Front Pharmacol. 2022;13:879690.","journal-title":"Front Pharmacol"},{"key":"1030_CR48","doi-asserted-by":"publisher","first-page":"e867","DOI":"10.1212\/WNL.0000000000006082","volume":"91","author":"S Janelidze","year":"2018","unstructured":"Janelidze S, Mattsson N, Stomrud E, Lindberg O, Palmqvist S, Zetterberg H, et al. CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease. Neurology. 2018;91:e867\u2013e77.","journal-title":"Neurology"},{"key":"1030_CR49","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1111\/jnc.14108","volume":"142","author":"Z Xu","year":"2017","unstructured":"Xu Z, Han K, Chen J, Wang C, Dong Y, Yu M, et al. Vascular endothelial growth factor is neuroprotective against ischemic brain injury by inhibiting scavenger receptor A expression on microglia. J Neurochem. 2017;142:700\u20139.","journal-title":"J Neurochem"},{"key":"1030_CR50","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.neuroscience.2015.07.070","volume":"304","author":"I Lonskaya","year":"2015","unstructured":"Lonskaya I, Hebron ML, Selby ST, Turner RS, Moussa CE. Nilotinib and bosutinib modulate pre-plaque alterations of blood immune markers and neuro-inflammation in Alzheimer\u2019s disease models. Neuroscience. 2015;304:316\u201327.","journal-title":"Neuroscience"},{"key":"1030_CR51","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1111\/bph.15221","volume":"178","author":"V Palomo","year":"2021","unstructured":"Palomo V, Nozal V, Rojas-Prats E, Gil C, Martinez A. Protein kinase inhibitors for amyotrophic lateral sclerosis therapy. Br J Pharmacol. 2021;178:1316\u201335.","journal-title":"Br J Pharm"},{"key":"1030_CR52","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1093\/hmg\/ddy143","volume":"27","author":"S Lee","year":"2018","unstructured":"Lee S, Kim S, Park YJ, Yun SP, Kwon SH, Kim D, et al. The c-Abl inhibitor, Radotinib HCl, is neuroprotective in a preclinical Parkinson\u2019s disease mouse model. Hum Mol Genet. 2018;27:2344\u201356.","journal-title":"Hum Mol Genet"},{"key":"1030_CR53","doi-asserted-by":"publisher","first-page":"eaaf3962","DOI":"10.1126\/scitranslmed.aaf3962","volume":"9","author":"K Imamura","year":"2017","unstructured":"Imamura K, Izumi Y, Watanabe A, Tsukita K, Woltjen K, Yamamoto T, et al. The Src\/c-Abl pathway is a potential therapeutic target in amyotrophic lateral sclerosis. Sci Transl Med. 2017;9:eaaf3962.","journal-title":"Sci Transl Med"},{"key":"1030_CR54","doi-asserted-by":"publisher","first-page":"e13332","DOI":"10.1111\/acel.13332","volume":"20","author":"HJ Lee","year":"2021","unstructured":"Lee HJ, Jeon SG, Kim J, Kang RJ, Kim SM, Han KM, et al. Ibrutinib modulates Abeta\/tau pathology, neuroinflammation, and cognitive function in mouse models of Alzheimer\u2019s disease. Aging Cell. 2021;20:e13332.","journal-title":"Aging Cell"},{"key":"1030_CR55","doi-asserted-by":"publisher","first-page":"684344","DOI":"10.3389\/fimmu.2021.684344","volume":"12","author":"J Kim","year":"2021","unstructured":"Kim J, Park JH, Park SK, Hoe HS. Sorafenib modulates the LPS- and abeta-induced neuroinflammatory response in cells, wild-type mice, and 5xFAD mice. Front Immunol. 2021;12:684344.","journal-title":"Front Immunol"},{"key":"1030_CR56","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.3390\/cells9071655","volume":"9","author":"KM Han","year":"2020","unstructured":"Han KM, Kang RJ, Jeon H, Lee HJ, Lee JS, Park H, et al. Regorafenib regulates AD pathology, neuroinflammation, and dendritic spinogenesis in cells and a mouse model of AD. Cells. 2020;9:1655.","journal-title":"Cells"},{"key":"1030_CR57","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1007\/s10875-011-9579-6","volume":"31","author":"O Crespo","year":"2011","unstructured":"Crespo O, Kang SC, Daneman R, Lindstrom TM, Ho PP, Sobel RA, et al. Tyrosine kinase inhibitors ameliorate autoimmune encephalomyelitis in a mouse model of multiple sclerosis. J Clin Immunol. 2011;31:1010\u201320.","journal-title":"J Clin Immunol"},{"key":"1030_CR58","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1016\/j.neuroscience.2009.05.019","volume":"162","author":"V Echeverria","year":"2009","unstructured":"Echeverria V, Burgess S, Gamble-George J, Zeitlin R, Lin X, Cao C, et al. Sorafenib inhibits nuclear factor kappa B, decreases inducible nitric oxide synthase and cyclooxygenase-2 expression, and restores working memory in APPswe mice. Neuroscience. 2009;162:1220\u201331.","journal-title":"Neuroscience"},{"key":"1030_CR59","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1016\/j.jalz.2018.06.2857","volume":"14","author":"GL Bowman","year":"2018","unstructured":"Bowman GL, Dayon L, Kirkland R, Wojcik J, Peyratout G, Severin IC, et al. Blood-brain barrier breakdown, neuroinflammation, and cognitive decline in older adults. Alzheimers Dement. 2018;14:1640\u201350.","journal-title":"Alzheimers Dement"},{"key":"1030_CR60","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1212\/WNL.0000000000002151","volume":"85","author":"S Janelidze","year":"2015","unstructured":"Janelidze S, Lindqvist D, Francardo V, Hall S, Zetterberg H, Blennow K, et al. Increased CSF biomarkers of angiogenesis in Parkinson disease. Neurology. 2015;85:1834\u201342.","journal-title":"Neurology"},{"key":"1030_CR61","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1038\/s41586-018-0119-x","volume":"557","author":"V Rothhammer","year":"2018","unstructured":"Rothhammer V, Borucki DM, Tjon EC, Takenaka MC, Chao CC, Ardura-Fabregat A, et al. Microglial control of astrocytes in response to microbial metabolites. Nature. 2018;557:724\u20138.","journal-title":"Nature"},{"key":"1030_CR62","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/d41586-018-05113-0","volume":"557","author":"H Wekerle","year":"2018","unstructured":"Wekerle H. Brain inflammatory cascade controlled by gut-derived molecules. Nature. 2018;557:642\u20133.","journal-title":"Nature"},{"key":"1030_CR63","doi-asserted-by":"publisher","first-page":"e1043","DOI":"10.1212\/NXI.0000000000001043","volume":"8","author":"A Cirac","year":"2021","unstructured":"Cirac A, Tsaktanis T, Beyer T, Linnerbauer M, Andlauer T, Grummel V, et al. The Aryl hydrocarbon receptor-dependent TGF-alpha\/VEGF-B ratio correlates with disease subtype and prognosis in multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2021;8:e1043.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"1030_CR64","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1002\/glia.20173","volume":"50","author":"V Waetzig","year":"2005","unstructured":"Waetzig V, Czeloth K, Hidding U, Mielke K, Kanzow M, Brecht S, et al. c-Jun N-terminal kinases (JNKs) mediate pro-inflammatory actions of microglia. Glia. 2005;50:235\u201346.","journal-title":"Glia"},{"key":"1030_CR65","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.freeradbiomed.2021.03.037","volume":"168","author":"Z Liu","year":"2021","unstructured":"Liu Z, Yao X, Sun B, Jiang W, Liao C, Dai X, et al. Pretreatment with kaempferol attenuates microglia-mediate neuroinflammation by inhibiting MAPKs-NF-kappaB signaling pathway and pyroptosis after secondary spinal cord injury. Free Radic Biol Med. 2021;168:142\u201354.","journal-title":"Free Radic Biol Med"},{"key":"1030_CR66","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.immuni.2020.12.010","volume":"54","author":"B Wu","year":"2021","unstructured":"Wu B, Zhang S, Guo Z, Bi Y, Zhou M, Li P, et al. The TGF-beta superfamily cytokine Activin-A is induced during autoimmune neuroinflammation and drives pathogenic Th17 cell differentiation. Immunity. 2021;54:308\u201323 e6.","journal-title":"Immunity"},{"key":"1030_CR67","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-019-1688-9","volume":"17","author":"J Zhang","year":"2020","unstructured":"Zhang J, Liu Y, Zheng Y, Luo Y, Du Y, Zhao Y, et al. TREM-2-p38 MAPK signaling regulates neuroinflammation during chronic cerebral hypoperfusion combined with diabetes mellitus. J Neuroinflammation. 2020;17:2.","journal-title":"J Neuroinflammation"},{"key":"1030_CR68","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-020-01809-1","volume":"17","author":"I Plastira","year":"2020","unstructured":"Plastira I, Bernhart E, Joshi L, Koyani CN, Strohmaier H, Reicher H, et al. MAPK signaling determines lysophosphatidic acid (LPA)-induced inflammation in microglia. J Neuroinflammation. 2020;17:127.","journal-title":"J Neuroinflammation"},{"key":"1030_CR69","doi-asserted-by":"publisher","first-page":"9364","DOI":"10.3390\/ijms22179364","volume":"22","author":"AD Caliz","year":"2021","unstructured":"Caliz AD, Yoo HJ, Vertii A, Dolan AC, Tournier C, Davis RJ, et al. Mitogen kinase kinase (MKK7) controls cytokine production in vitro and in vivo in mice. Int J Mol Sci. 2021;22:9364.","journal-title":"Int J Mol Sci"},{"key":"1030_CR70","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1111\/imcb.12426","volume":"99","author":"SP Preston","year":"2021","unstructured":"Preston SP, Doerflinger M, Scott HW, Allison CC, Horton M, Cooney J, et al. The role of MKK4 in T-cell development and immunity to viral infections. Immunol Cell Biol. 2021;99:428\u201335.","journal-title":"Immunol Cell Biol"},{"key":"1030_CR71","doi-asserted-by":"publisher","first-page":"113797","DOI":"10.1016\/j.bcp.2020.113797","volume":"174","author":"T Yu","year":"2020","unstructured":"Yu T, Wang Z, Jie W, Fu X, Li B, Xu H, et al. The kinase inhibitor BX795 suppresses the inflammatory response via multiple kinases. Biochem Pharmacol. 2020;174:113797.","journal-title":"Biochem Pharm"},{"key":"1030_CR72","doi-asserted-by":"publisher","DOI":"10.1186\/1742-2094-7-99","volume":"7","author":"MJ Wang","year":"2010","unstructured":"Wang MJ, Huang HY, Chen WF, Chang HF, Kuo JS. Glycogen synthase kinase-3beta inactivation inhibits tumor necrosis factor-alpha production in microglia by modulating nuclear factor kappaB and MLK3\/JNK signaling cascades. J Neuroinflammation. 2010;7:99.","journal-title":"J Neuroinflammation"},{"key":"1030_CR73","doi-asserted-by":"publisher","first-page":"9944880","DOI":"10.1155\/2021\/9944880","volume":"2021","author":"N Lee","year":"2021","unstructured":"Lee N, Heo YJ, Choi SE, Jeon JY, Han SJ, Kim DJ, et al. Anti-inflammatory effects of empagliflozin and gemigliptin on LPS-stimulated macrophage via the IKK\/NF-kappaB, MKK7\/JNK, and JAK2\/STAT1 signalling pathways. J Immunol Res. 2021;2021:9944880.","journal-title":"J Immunol Res"},{"key":"1030_CR74","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1021\/acschembio.6b01060","volume":"12","author":"KK Deibler","year":"2017","unstructured":"Deibler KK, Mishra RK, Clutter MR, Antanasijevic A, Bergan R, Caffrey M, et al. A chemical probe strategy for interrogating inhibitor selectivity across the MEK kinase family. ACS Chem Biol. 2017;12:1245\u201356.","journal-title":"ACS Chem Biol"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41401-022-01030-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-022-01030-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-022-01030-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T13:03:05Z","timestamp":1684760585000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41401-022-01030-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,19]]},"references-count":74,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["1030"],"URL":"https:\/\/doi.org\/10.1038\/s41401-022-01030-1","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,19]]},"assertion":[{"value":"5 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}